NCT00483704

Multiple Attacks Study to Compare the Efficacy and Safety of MK-0974 With Placebo for Acute Migraine (MK-0974-031)

A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Multiple Attacks Study to Compare the Efficacy and Safety of Oral MK-0974 With Placebo for the Acute Treatment of Migraine With or Without Aura

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,935 (actual)
• Sponsor: Merck Sharp & Dohme LLC · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to assess the safety and efficacy of telcagepant (MK-0974) in acute treatment of multiple migraine attacks with or without aura. Primary hypotheses of this study are that telcagepant is superior to placebo, as measured by the proportion of participants who have pain freedom, pain relief, pain freedom consistency, pain relief consistency, and absence of photophobia, phonophobia, and nausea at 2 hours post-dose.

Conditions

• Migraines

Interventions

Type	Name	Description
DRUG	Telcagepant 140 mg	Telcagepant 140 mg tablets
DRUG	Talcagepant 280 mg	Telcagepant 280 mg tablets
DRUG	Placebo	Placebo tablets

Timeline

• Start date: 2008-08-14
• Primary completion: 2009-03-25
• Completion: 2009-03-25
• First posted: 2007-06-07
• Last updated: 2018-10-18
• Results posted: 2014-08-29